Existing studies have shown that advanced NSCLC with the HER2 exon 20 YVMA insertion mutation has a poorer prognosis compared to other HER2 mutation types and exhibits limited efficacy to both chemotherapy and targeted therapies. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.